US 11,896,732 B2 · Compacted hemostatic cellulosic aggregates

Abstract

The present invention is directed to a hemostatic material comprising a compacted, hemostatic aggregates of cellulosic fibers. In some aspects, the hemostatic material further includes additives, such as carboxymethyl cellulose (CMC) or other polysaccharides, calcium salts, anti-infective agents, hemostasis promoting agents, gelatin, collagen, or combinations thereof. In another aspect, the present invention is directed to a method of making the hemostatic materials described above by compacting a cellulosic-based material into hemostatic aggregates. In another aspect, the present invention is directed to a method of treating a wound by applying hemostatic materials described above onto and/or into the wound of a patient.

Claims16

Dependent claims

A method of treating a wound comprising applying a plurality of hemostatic aggregates onto and/or into the wound of a patient, wherein the plurality hemostatic aggregates are made by a method of making comprising the steps of:

a) milling a cellulosic source material to form fibers;
b) humidifying the fibers to water content of between 11.0% and 20% by weight;
c) roller compacting the fibers to form hemostatic aggregates;
d) sieving the hemostatic aggregates;
e) dehumidifying the hemostatic aggregates to a moisture content of less than 5.5% determined by loss on drying;
and
f) optionally dosing the resulting hemostatic aggregates into storage containers or into delivery devices.

4 more elements

Dependencies are inferred from the claim text.

Facts

Application

17/559,372Filed 22 Dec 2021 · division

Priority

6 Nov 2015

Published

US 2022/0184272 A116 Jun 2022

Granted

13 Feb 2024

Term ends

Not estimatedThe source records don’t support an estimate.

Classification10 codes

A61L 26/0023
Containing macromolecular materials: polysaccharides
A61L 15/24
Containing macromolecular materials: macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives…
A61L 26/0061
Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form: use of materials characterised by their…
A61P 7/04
Drugs for disorders of the blood or the extracellular fluid: antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Family

Application62/251,773Us provisional application · filed 6 Nov 2015

Application62/371,954Us provisional application · filed 8 Aug 2016

Application62/408,176Us provisional application · filed 14 Oct 2016

Application15/337,337Parent of this division · filed 28 Oct 2016

Application16/031,111Parent of this division · filed 10 Jul 2018

US 10,034,957 B2Parent of this division · filed 31 Jul 2018

US 2022/0184272 A1Pre-grant publication · published 16 Jun 2022

US 11,235,085 B2Parent of this division

US 2017/0128618 A1Published application

US 2018/0311405 A1Published application

US 11,896,732 B2This patent

From the US filing history. Foreign family members aren’t listed.

Compacted hemostatic cellulosic aggregates

Life of this patent

Compacted hemostatic cellulosic aggregates

Life of this patent

Abstract

Claims16